Latest news with #CellebriteDI
Yahoo
2 days ago
- Business
- Yahoo
Cellebrite (CLBT) Cheers on 3rd Day After Swing to Profit
We recently published . Cellebrite DI Ltd. (NASDAQ:CLBT) is one of the top performers on Thursday. Cellebrite rallied for a third consecutive day on Thursday, jumping 9.29 percent to end at $15.29 apiece after swinging to profitability in the second quarter of the year. In its updated report, Cellebrite DI Ltd. (NASDAQ:CLBT) climbed to a net income of $19.48 million from a $23.8 million net loss in the same period last year. Revenues increased by 18 percent to $113.28 million from $95.7 million. In the first half, the company posted a net profit of $36.88 million, reversing a $95.18 million net loss in the same comparable period. Revenues were higher by 19 percent to $220.8 million versus $185.3 million year-on-year. Copyright: aijohn784 / 123RF Stock Photo Despite strong figures, Cellebrite DI Ltd. (NASDAQ:CLBT) lowered its outlook on key metrics for the full-year period, with revenues now pegged at $465 million to $475 million, versus the $470 million to $485 million targeted previously. The new outlook represents a 16 to 18 percent annual growth, versus the 17 to 21 percent expected prior. For the third quarter alone, revenues were targeted at $121 million to $126 million, or a 13 to 18 percent growth year-on-year. Following the performance, investment firm Needham lowered its price target for Cellebrite DI Ltd. (NASDAQ:CLBT) to $18 from $24 previously, but maintained a 'buy' recommendation on the stock. While we acknowledge the potential of CLBT as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the .
Yahoo
16-05-2025
- Business
- Yahoo
Cellebrite DI First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag
Revenue: US$107.5m (up 20% from 1Q 2024). Net income: US$17.4m (up from US$71.4m loss in 1Q 2024). Profit margin: 16% (up from net loss in 1Q 2024). The move to profitability was primarily driven by lower expenses. EPS: US$0.073 (up from US$0.36 loss in 1Q 2024). This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. All figures shown in the chart above are for the trailing 12 month (TTM) period Revenue missed analyst estimates by 1.7%. Earnings per share (EPS) exceeded analyst estimates by 53%. Looking ahead, revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Software industry in the US. Performance of the American Software industry. The company's shares are down 10% from a week ago. Be aware that Cellebrite DI is showing 1 warning sign in our investment analysis that you should know about... Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
